Janssen Research & Development, LLC psychedelic research trials
Data as of 11 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
Janssen Research & Development, LLC is listed with 9 registered studies counted here, in Birmingham, United States. By compound: 9 ketamine. By registry status: 9 completed. By phase: 3 phase 2, 5 phase 3 and 1 phase 4. Reported start years run from 2012 (earliest) to 2020 (latest).
Institution name, city and country are copied from the research site linked to each registry record. A study counts once per institution, and a study tagged with more than one compound is counted under each compound.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
At a glance
- 9 registered studies are counted on this page.
By compound
| Compound hub | Studies |
|---|---|
| Ketamine | 9 |
By registry status
| Status | Studies | Share |
|---|---|---|
| Completed | 9 | 100% |
By phase
| Phase | Studies | Share |
|---|---|---|
| Phase 2 | 3 | 33% |
| Phase 3 | 5 | 56% |
| Phase 4 | 1 | 11% |
Registered studies
All counted studies, newest start first. The order is not a ranking and says nothing about quality. Titles are quoted from the registry. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.
| Title as registered | Registry ID | Status | Phase | Start | Compound |
|---|---|---|---|---|---|
| A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression | NCT04599855 | Completed | Phase 4 | 2020-11-04 | Ketamine |
| 54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide | NCT03039192 | Completed | Phase 3 | 2017-06-09 | Ketamine |
| A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression | NCT02782104 | Completed | Phase 3 | 2016-06-09 | Ketamine |
| A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression | NCT02493868 | Completed | Phase 3 | 2015-10-01 | Ketamine |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression | NCT02417064 | Completed | Phase 3 | 2015-08-10 | Ketamine |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression | NCT02418585 | Completed | Phase 3 | 2015-08-07 | Ketamine |
| A Double-blind Study to Assess the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Participants Who Are Assessed to be at Imminent Risk for Suicide | NCT02133001 | Completed | Phase 2 | 2014-05-23 | Ketamine |
| A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression | NCT01998958 | Completed | Phase 2 | 2014-01-27 | Ketamine |
| A Study of Ketamine in Patients With Treatment-resistant Depression | NCT01627782 | Completed | Phase 2 | 2012-08-06 | Ketamine |
About this data
Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals. A registry listing is not evidence of safety, benefit or results.